Tadalafil for Obesity

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
ObesityTadalafil 20 MG - Drug
Eligibility
19 - 50
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing whether a drug that helps blood flow can also help reduce fat storage in obese people.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 4 Secondary · Reporting Duration: 12 weeks

12 weeks
Subcutaneous adipose tissue expression of UCP1 (normalized expression units)
Thermoneutral FSF of WAT at the level of the umbilicus at 12 Weeks.
Baseline to 12 Weeks
Homeostatic Index of Insulin Resistance
Resting energy expenditure
Baseline to 12 weeks
BAT perfusion under thermoneutral and cold conditions
Change in BNP concentration during cold exposure
Change in free fatty acid level during cold exposure
Change in whole body subcutaneous and visceral fat mass
Cold-exposed fat signal fraction of white adipose tissue and grown adipose tissue
Subcutaneous adipose tissue gene expression of mitochondrial genes (normalized expression units)
Subcutaneous adipose tissue natriuretic peptide receptor expression
Adipose tissue

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

2 Treatment Groups

Tadalafil
1 of 2
Placebo
1 of 2

Active Control

Non-Treatment Group

100 Total Participants · 2 Treatment Groups

Primary Treatment: Tadalafil · Has Placebo Group · Phase 2

Tadalafil
Drug
ActiveComparator Group · 1 Intervention: Tadalafil 20 MG · Intervention Types: Drug
Placebo
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 12 weeks

Who is running the clinical trial?

Vanderbilt University Medical CenterLead Sponsor
772 Previous Clinical Trials
600,452 Total Patients Enrolled
34 Trials studying Obesity
6,859 Patients Enrolled for Obesity
Evan Brittain, MD, MSciPrincipal Investigator - VUMC
Vanderbilt University Medical Center

Eligibility Criteria

Age 19 - 50 · All Participants · 2 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you: